Trial Profile
NK1 Receptor Antagonist vs Placebo in the Treatment of Overactive Bladder Symptoms
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Casopitant (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors GSK
- 04 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 08 Nov 2006 New trial record.